Markets:

Overview

News

Currencies

International

Treasuries

Gossamer Bio, Inc. - Common Stock (NQ:GOSS)

9.180 -0.130 (-1.40%)

Delayed Quote Updated: 10:15 AM EDT, Oct 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Gossamer Bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension

September 23, 2026

From Gossamer Bio, Inc.

Via Business Wire

Gossamer Bio Appoints Greg Ciongoli to Board of Directors

September 16, 2026

From Gossamer Bio, Inc.

Via Business Wire

Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split

September 11, 2026

From Gossamer Bio, Inc.

Via Business Wire

Gossamer Bio Announces 1-for-80 Reverse Stock Split

September 09, 2026

From Gossamer Bio, Inc.

Via Business Wire

Gossamer Bio to Present at Cantor Global Healthcare Conference

September 04, 2026

From Gossamer Bio, Inc.

Via Business Wire

Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval

August 21, 2026

From Gossamer Bio, Inc.

Via Business Wire

Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update

August 13, 2026

From Gossamer Bio, Inc.

Via Business Wire

Undervalued Stocks in Focus: IGC, CISS, TOON, GOSS, KIDZ Enter Catalyst-Rich Growth Phase

July 28, 2026

Via AB Newswire

Topics Artificial Intelligence

Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update

July 27, 2026

From Gossamer Bio, Inc.

Via Business Wire

Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants

July 01, 2026

From Gossamer Bio, Inc.

Via Business Wire

Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

June 17, 2026

From Gossamer Bio, Inc.

Via Business Wire

Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

June 03, 2026

From Gossamer Bio, Inc.

Via Business Wire

CLASS ACTION DEADLINE TONIGHT: Gossamer Bio (GOSS) Investors Who Suffered Losses Encouraged to Contact Faruqi & Faruqi Before June 1, 2026 Securities Class Action Deadline

June 01, 2026

From Faruqi & Faruqi, LLP

Via Business Wire

GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

June 01, 2026

From The Schall Law Firm

Via Business Wire

Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

June 02, 2026

From Gossamer Bio, Inc.

Via Business Wire

GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

May 31, 2026

From Schall Law

Via GlobeNewswire

GOSSAMER BIO DEADLINE MONDAY JUNE 1st: Bragar Eagel & Squire, P.C. Urges Gossamer Bio, Inc. (NASDAQ:GOSS) Investors with Large Losses to Contact the Firm Before Monday June 1st

May 29, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

Deadline Soon: Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

May 29, 2026

From The Law Offices of Frank R. Cruz

Via Business Wire

GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

May 28, 2026

From Schall Law

Via GlobeNewswire

GOSSAMER DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Gossamer Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – GOSS

May 27, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Urges Gossamer Bio, Inc. (NASDAQ:GOSS) Investors with Large Losses to Contact the Firm Before Monday June 1st

May 26, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Gossamer Bio, Inc. of Class Action Lawsuit and Upcoming Deadlines – GOSS

May 26, 2026

From Pomerantz LLP

Via GlobeNewswire

DEADLINE APPROACHING: Berger Montague Advises Gossamer Bio, Inc. (NASDAQ: GOSS) Investors to Inquire About a Securities Fraud Class Action by June 1, 2026

May 26, 2026

From Berger Montague

Via GlobeNewswire

GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

May 25, 2026

From Schall Law

Via GlobeNewswire

GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

May 21, 2026

From Schall Law

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Gossamer Bio, Inc. of Class Action Lawsuit and Upcoming Deadlines – GOSS

May 19, 2026

From Pomerantz LLP

Via GlobeNewswire

GOSS UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026

May 18, 2026

From Faruqi & Faruqi, LLP

Via Business Wire

GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

May 18, 2026

From Schall Law

Via GlobeNewswire

Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support

May 18, 2026

From Gossamer Bio, Inc.

Via Business Wire

Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update

May 18, 2026

From Gossamer Bio, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.